Nanoparticle-based agents in preclinical and clinical trials for brain tumors (clinicaltrials.gov)
| Name | Material | Target ligand | Therapeutic agent | Size (nm) | Status |
|---|---|---|---|---|---|
| Organic/Polymer | |||||
| NL CPT-11 (Clarke et al., 2017) | Liposome | — | irinotecan | 96–101 | Phase I NCT00734682 |
| SGT-53 (Camp et al., 2013) | Liposome | transferrin | wild-type P53 gene | 90 | Phase II NCT02340156 |
| SGT-94 (Siefker-Radtke et al., 2016) | Liposome | transferrin | RB94 gene | 108 | Phase I NCT01517464 |
| 2B3-101 (Gaillard et al., 2014) | Liposome | glutathione | doxorubicin | 95 | Phase I/IIa NCT01386580 |
| Inorganic | |||||
| Cornell dots (Phillips et al., 2014) | silica nanoparticles | cyclic arginine–glycine–aspartic acid (cRGDY) peptides | — | 7 | Phase 0 NCT01266096 |
| NU-0129 | gold nanoparticles | spherical nucleic acid for BCL2L12 | — | Phase 0/1 NCT03020017 | |
| NanoTherm (Maier-Hauff et al., 2011) | iron oxide | — | — | 15 | Approved in Europe in 2013 |